Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020069405 - CD22 CHIMERIC ANTIGEN RECEPTOR (CAR) THERAPIES

Publication Number WO/2020/069405
Publication Date 02.04.2020
International Application No. PCT/US2019/053601
International Filing Date 27.09.2019
IPC
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 14/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
CPC
A61K 2039/545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
545characterised by the dose, timing or administration schedule
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 14/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C07K 16/2803
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
C07K 2317/622
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
60characterized by non-natural combinations of immunoglobulin fragments
62comprising only variable region components
622Single chain antibody (scFv)
C07K 2317/73
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Applicants
  • NOVARTIS AG [CH]/[CH]
  • THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US]/[US]
Inventors
  • GRUPP, Stephan
Agents
  • COLLAZO, Diana, M.
Priority Data
62/738,38728.09.2018US
62/744,94712.10.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CD22 CHIMERIC ANTIGEN RECEPTOR (CAR) THERAPIES
(FR) THÉRAPIES PAR RÉCEPTEUR ANTIGÉNIQUE CHIMÉRIQUE (CAR) DE CD22
Abstract
(EN)
The invention provides compositions and methods for treating cancer, e.g., hematological cancer, by administering a CD22 CAR-expressing cell described herein according to a dosage regimen described herein. Also disclosed are methods of making and compositions comprising the same.
(FR)
L'invention concerne des compositions et des méthodes de traitement du cancer, par exemple du cancer hématologique, par l'administration d'une cellule exprimant un CAR de CD22 décrite dans la description de l'invention selon un schéma posologique décrit dans la description de l'invention. L'invention concerne également des procédés de préparation et des compositions comprenant celle-ci.
Latest bibliographic data on file with the International Bureau